We’re #hiring a new Senior Clinical Research Associate / Senior Field Clinical Specialist (with focus proctoring duties) in France. Apply today or share this post with your network.
CorFlow
Herstellung medizinischer Geräte
CorFlow is developing a system that will be the first to detect & treat microvascular obstruction (MVO) in real time.
Info
CorFlow was founded on the belief that current PCI and cardiac care remains suboptimal due the fact that underlying microvascular dysfunction and obstruction is not detected and treated adequately. CorFlow believes, like much of the medical community, that the next frontier of innovation and positive impact on clinical outcomes in cardiology and beyond will come from the microvascular space. Our first solution is a system that will be the first to diagnose microvascular obstruction (MVO) in real time during PCI and serve as a treatment platform in the cath lab. There are ongoing clinical studies to demonstrate safety and efficacy so the platform remains investigational use only. Our Mission - To extend and improve the quality of human life with a relentless pursuit to solve unmet medical needs Our Vision - To be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists Our Values - To place quality above all else - To treat all people with the highest moral and ethical standards - To be a fair partner to everyone we work with and serve - To foster inclusion, transparency, well-being and positivity with our employees while chasing ambitious goals - To embrace a holistic view of success, inclusive of environmental, social and governance targets we hold ourselves accountable for CorFlow was founded in 2016 in Baar, Switzerland and now has offices in both Baar and Bern, Switzerland. The company has been financed by a combination of seed funding by angel investors, Venture Capital, and grants via a partnership with the Swiss government that awards significant innovation to improve health care. The Series A financing round closed in 2021, and a Series B round is targeted for 2023. Our CEO is Paul Mead, who brings close to 20 years of operational experience in medtech working for Medtronic. The Chairman of our Board is Rick Geoffrion, CEO of Cyrano Therapeutics.
- Website
-
https://corflow.com/
Externer Link zu CorFlow
- Branche
- Herstellung medizinischer Geräte
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Baar, Switzerland
- Art
- Privatunternehmen
- Gegründet
- 2016
- Spezialgebiete
- cardiology, medical devices, medtech, interventional cardiology, femtech, vascular, diagnostics, drug delivery, venture capital und startup
Orte
-
Primär
Wegbeschreibung
Baar, Switzerland , CH
Beschäftigte von CorFlow
-
Judy Gonzalez
Medical Device Marketing
-
Reggie Walton, MBA
Builder of Clinical Operations Teams | Mentor & Team Development Champion | Cardiovascular & Medical Device Specialist | Clinical Engineer | Veteran…
-
Giovanna Catalano
Clinical Project Manager presso CorFlow Therapeutics AG
-
Lennart Ivarsson, PhD
Clinical Operations Leader and Expert I 🌎Global Clinical Studies I 🎯Deliver on quality, time and budget I 🔹Mentoring I Strategy I Regulatory
Updates
-
We are excited to see you all at #TCT2024 in just under a week! Emma van Eeden, Paul Mead, Lennart Ivarsson, PhD Reggie Walton, MBA, and Sabrina Frey, will all be there, so please reach out via LinkedIn, WhatsApp, X or just plain ol' telephone! Looking forward to our FIH data release, MOCA I, as well as all the LBCT and more! #MVO #STEMI #Precision
-
-
We are thrilled to announce that Reggie Walton, MBA has joined our team as Head of US Clinical Operations, as the company’s first US hire. This is a significant moment in CorFlow's journey as we expand our operations to enable the execution of our pivotal trial and beyond. Reggie brings significant expertise in managing clinical trials "end to end" in cardiovascular medical devices, most recently at Edwards and Abiomed with leadership roles for landmark studies. Reggie holds a Master of Business Administration and a Bachelor of Science in Electrical Engineering and will remain located in Texas with his family. Please join us in welcoming Reggie to our growing team!
-
-
We are excited to announce that Anastasia Milusev, PhD in Biomedical Sciences, has joined our team as an R&D Scientist. Her experience in cardiovascular research and continuation of her in vitro work on CorFlow's Controlled Flow Infusion (CoFI) solution in collaboration with the University of Bern will be extremely valuable to our future. Please join us in welcoming Anastasia and wishing her a great start in her new role!
-
-
We are excited to announce that Julian Krebs, PhD in Medical Imaging, joined our team as R&D Data Scientist! His experience in medical signal analysis and AI will be extremely valuable for our organization. Please join us in welcoming Julian and wishing him a great start in his new role!
Dieser Inhalt ist hier nicht verfügbar.
Mit der LinkedIn App können Sie auf diese und weitere Inhalte zugreifen.
-
Following the Series B announcement yesterday, we wanted to recognize our supporting partners who have contributed their expertise to reach this milestone - MCRA, an IQVIA business, Eversheds Sutherland, Chris Bolten, Frontcourt Group, Walder Wyss Ltd., Innosuisse, ARTORG Center for Biomedical Engineering Research, University of Bern, ETH Zürich, Universitätsspital Zürich, Bytec Medizintechnik GmbH, OpSens (Haemonetics), WILDDESIGN, Benkana Interfaces GmbH & Co. KG and VistaMed.
https://lnkd.in/exu3ntSN We are absolutely thrilled to announce the completion of Series B financing raising Euro 44 million. Building on our first-in-human MOCA I study we are now excited to move to the next phase of our clinical trial program and expanding our team. 🌐 https://corflow.com/news Microvascular Obstruction remains one of the biggest clinical challenges in treating heart attack patients and is one of the most important predictors of poor outcomes. We are delighted that our funding partners have the same vision and we recognize the responsibility this investment comes with, which is why this funding is directed towards two large clinical trials. The International Pivotal Trial (MOCA II) aimed at achieving market clearance in the USA, will be led by Timothy Henry (The Christ Hospital, Cincinnati, USA) and Valgimigli Marco (Cardiocentro Ticino Institute, Lugano, Switzerland). Secondly, we plan to conduct a randomized, controlled, trial in Europe designed to further evaluate therapies delivered locally with our technology immediately after a diagnosis of MVO post PPCI, which will be led by Giovanni Luigi De Maria MD, PhD, FESC (Oxford University Hospitals Trust, UK) and Colin Berry (University of Glasgow and NHS Golden Jubilee National Hospital, UK). Unique technology is born out of excellent collaboration. We would like to thank our research and technical partners Innosuisse, ARTORG Center for Biomedical Engineering Research, University of Bern, ETH Zürich, Universitätsspital Zürich, Bytec Medizintechnik GmbH, WILDDESIGN, Benkana Interfaces GmbH & Co. KG and VistaMed for their ongoing support. #MVO #VC #STEMI #CorFlow #Precision #UnmetNeet #VentureCapital #Startups #Innovation #InterventionalCardiology #HeartAttack #Microvascular #MedTech #Cardiovascular #Pharma
-
https://lnkd.in/exu3ntSN We are absolutely thrilled to announce the completion of Series B financing raising Euro 44 million. Building on our first-in-human MOCA I study we are now excited to move to the next phase of our clinical trial program and expanding our team. 🌐 https://corflow.com/news Microvascular Obstruction remains one of the biggest clinical challenges in treating heart attack patients and is one of the most important predictors of poor outcomes. We are delighted that our funding partners have the same vision and we recognize the responsibility this investment comes with, which is why this funding is directed towards two large clinical trials. The International Pivotal Trial (MOCA II) aimed at achieving market clearance in the USA, will be led by Timothy Henry (The Christ Hospital, Cincinnati, USA) and Valgimigli Marco (Cardiocentro Ticino Institute, Lugano, Switzerland). Secondly, we plan to conduct a randomized, controlled, trial in Europe designed to further evaluate therapies delivered locally with our technology immediately after a diagnosis of MVO post PPCI, which will be led by Giovanni Luigi De Maria MD, PhD, FESC (Oxford University Hospitals Trust, UK) and Colin Berry (University of Glasgow and NHS Golden Jubilee National Hospital, UK). Unique technology is born out of excellent collaboration. We would like to thank our research and technical partners Innosuisse, ARTORG Center for Biomedical Engineering Research, University of Bern, ETH Zürich, Universitätsspital Zürich, Bytec Medizintechnik GmbH, WILDDESIGN, Benkana Interfaces GmbH & Co. KG and VistaMed for their ongoing support. #MVO #VC #STEMI #CorFlow #Precision #UnmetNeet #VentureCapital #Startups #Innovation #InterventionalCardiology #HeartAttack #Microvascular #MedTech #Cardiovascular #Pharma
CorFlow Therapeutics AG Completes €44 Million Series B Financing to Support the Advancement of a Novel Diagnostic and Drug Delivery Platform for Microvascular Obstruction (MVO) in Heart Attack Patients
businesswire.com